• Tamsulosin: Research Context and Evidence Limits

  2026-10-09

  A source-grounded overview of Tamsulosin research, covering α1A-adrenergic pharmacology, conceptual applications in urology and receptor signaling, reported clinical outcome claims, evidence quality, and the limitations of applying supplier summaries or unrelated prostate-cancer findings to new research questions.

• GDC-0941 and PI3K/Akt Signaling in Cancer Research

  2026-10-09

  GDC-0941 is a preclinical PI3K inhibitor used to investigate PI3K/Akt signaling, tumor-cell survival, and treatment resistance. Supplier-reported findings support pathway engagement in several cancer models, while a 2024 liver cancer study provides an important but indirect rationale for examining PI3K/Akt signaling in liver cancer stem-cell biology. The available evidence remains preclinical and does not establish clinical efficacy or demonstrate that GDC-0941 directly targets DRD4-driven liver cancer stem cells.

• Biomimetic Chromatography for Lung Permeability

  2026-10-08

  The reference study compares two mass-spectrometry-compatible biomimetic chromatography platforms for modelling pulmonary drug permeability: immobilised artificial membrane liquid chromatography and open-tubular capillary electrochromatography. Its findings indicate that IAM-LC provides a robust permeability-screening signal, while OT-CEC-MS contributes complementary information about phospholipid-specific drug–membrane interactions.

• Apigenin's Translational Edge: HDAC to Neuroprotection

  2026-10-08

  Apigenin is emerging as a research bridge between HDAC-linked oncology biology and network-guided neuroprotection. This evidence-focused analysis examines the mechanistic rationale, model-specific findings, translational boundaries, competitive landscape, and strategic questions that should guide future studies.

• PXR Activation, Liver Regeneration, and CYP Activity

  2026-10-07

  Bi et al. show in rats that activation of the pregnane X receptor can connect liver enlargement and regeneration with increased functional activity of CYP3A1/2 and CYP2C6/11. The study is valuable because it evaluates metabolic performance alongside structural recovery, while its rat-specific model limits direct translation to human drug disposition.

• Anlotinib hydrochloride: Mechanism & Evidence

  2026-10-07

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor with supplier-reported activity against VEGFR2, PDGFRβ, and FGFR1. Available evidence supports anti-angiogenic mechanism studies, while a single case report provides only low-level clinical evidence for activity in desmoplastic small round cell tumor.

• Tamsulosin: Mechanism, Evidence, and Research Limits

  2026-10-06

  Tamsulosin is a selective α1A-adrenergic receptor antagonist linked to smooth muscle relaxation in the prostate, bladder neck, and ureter. Reported evidence supports research interest in ureteral stone expulsion and postoperative urinary retention, but the supplied prostate-cancer testosterone study does not evaluate Tamsulosin.

• USP36-Snail1 Axis in Ribotoxic Stress

  2026-10-06

  The reference study identifies a JNK-USP36-Snail1 mechanism that allows solid-tumor cells to preserve nucleolar ribosome biogenesis during ribotoxic stress. Its findings help explain why homoharringtonine can be effective in leukemia yet show limited activity against solid tumors, while supporting a combination strategy that targets this adaptive survival response.

• Caspofungin in Resistant Candida Research

  2026-10-05

  A source-grounded overview of Caspofungin research context, its role as a glucan-synthesis comparator, and what a 2021 Candida auris study shows about evidence strength, azole resistance, and preclinical applicability.

• Baicalin and Adult Visual Plasticity: Evidence Overview

  2026-10-04

  A source-grounded overview of baicalin research, focusing on adult amblyopia, ocular dominance plasticity, proposed GABAergic mechanisms, oncology-related claims, evidence strength, and translational limitations.

• GSK621: AMPK Agonism in AML Research

  2026-10-03

  GSK621 is an AMPK agonist used as a research probe for energy sensing, lipid metabolism, autophagy, and acute myeloid leukemia research. Product-level evidence supports AMPK pathway activation and AML-associated phenotypes, while a 2024 Immunity study defines a separate 25-hydroxycholesterol–AMPK mechanism in tumor-associated macrophages.

• Recombinant Mouse IFN-γ for MASH-HCC Assays

  2026-10-01

  Use Recombinant Mouse IFN-γ as a defined cytokine challenge to distinguish impaired tumor-cell responsiveness from bile acid-driven antigen-presentation failure in MASH-HCC models. This workflow combines dose-response testing, MHC-I readouts, and immune-cell co-culture with practical controls for reproducibility.

• A-1331852: BCL-XL Inhibitor Workflow Guide

  2026-10-01

  Build cleaner mitochondrial apoptosis experiments with A-1331852, a selective BCL-XL inhibitor suited to target-engagement, dependency-mapping, and senescent-cell elimination studies. This guide translates published BH3-mimetic findings into practical assay design, combination testing, and troubleshooting workflows.

• Palmitic acid: Protocol and QC Guide

  2026-10-01

  Palmitic acid (hexadecanoic acid, SKU N2456) provides a characterized saturated long-chain fatty acid for solvent-controlled studies of lipid metabolism, inflammation, insulin signaling, and protein palmitoylation. It should be prepared in ethanol or DMSO rather than added directly to aqueous systems, and freshly prepared solutions are preferred over long-term storage.

• HotStart Universal 2X Green qPCR Master Mix Workflow

  2026-09-30

  Build a reproducible real-time PCR gene expression analysis workflow for fusion transcripts, pathway markers, and treatment-response studies. This guide shows how hot-start chemistry, Green I fluorescence, ROX normalization, and melt curve analysis can strengthen assay specificity without obscuring the limits of dye-based detection.

8018 records 1/535 page Next 12345 下5页 Last page